SSA
BCTX

SSA Swiss Advisors’s Briacell Therapeutics BCTX Stock Holding History

SSA Swiss Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121 Buy
+37
New +$136 ﹤0.01% 107
2026
Q1 		– Sell
-37
Closed -$264 – 95
2025
Q4 		$264 Buy
+37
New +$390 ﹤0.01% 102

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LCM
LuminArx Capital Management New York $224M AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

SSA Swiss Advisors's BCTX Position: Q2 2026 in Review

SSA Swiss Advisors opened a new position in Briacell Therapeutics (BCTX) in Q2 2026: 37 shares worth $121. The stake represents ﹤0.01% of the portfolio and ranks #107 among its holdings. This is a return to the name: SSA Swiss Advisors previously reported a position in BCTX as recently as Q4 2025.

SSA Swiss Advisors first reported a position in BCTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $264 in Q4 2025. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • SSA Swiss Advisors held 37 shares of Briacell Therapeutics worth $121 as of Q2 2026.
  • Briacell Therapeutics was a new SSA Swiss Advisors position in Q2 2026.
  • Briacell Therapeutics made up ﹤0.01% of SSA Swiss Advisors's portfolio in Q2 2026, its #107 holding.
  • SSA Swiss Advisors first reported a position in Briacell Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SSA Swiss Advisors's Briacell Therapeutics position peaked at $264 in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on SSA Swiss Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.